1. ENLIGHTEN 2 trial met its primary endpoint with LYR-210's significant improvement in CRS. 2. LYR-210 showed statistically significant improvements in key secondary endpoints at 24 weeks. 3. Pooled data indicates LYR-210's consistent efficacy for CRS patients with nasal polyps. 4. Lyra plans to pursue FDA NDA submission based on positive trial data. 5. LYR-210 demonstrates a potential new treatment pathway for CRS patients underserved by current options.

1. MDaudit to acquire Streamline for $5.34 per share, 138% premium. 2. Transaction valued at approximately $37.4 million, including debt. 3. Merger aims to enhance billing compliance and revenue integrity solutions. 4. Streamline will become a private company post-merger; stock delisted. 5. MDaudit relies on cash and credit to fund the acquisition.

1. CollPlant received a $2 million milestone payment from AbbVie. 2. Regenerative breast implant program shows promising preclinical results. 3. Dermal filler development continues, with clinical trials underway. 4. Cost-cutting measures reduced workforce by 20% to optimize resources. 5. Cash balance as of March 31, 2025, was $10.7 million.

1. Zeo Energy to acquire Heliogen in an all-stock transaction. 2. Merger aims to enhance long-duration energy storage capabilities. 3. Transaction expected to close in Q3 2025, subject to conditions. 4. Acquisition will strengthen Zeo's commercial and utility-scale energy platform. 5. Heliogen stockholders stand to benefit from growth opportunities.

1. RRGB reported a revenue increase to $392.4 million, up by $3.8 million. 2. Net income improved significantly to $1.2 million, reversing a $9.5 million loss. 3. Adjusted EBITDA surged 108.2% to $27.9 million, reflecting operational efficiency gains. 4. RRGB repaid $17.8 million in debt, enhancing financial stability. 5. Projected comparable restaurant sales to decline by 3% next quarter.

1. NuCana announces expansion of NUC-7738 study for resistant melanoma. 2. Initial data from NUC-7738 expected in Q4 2025; final data in 2026. 3. Cash runway extended into Q4 2026, supporting key milestones. 4. Positive results for NUC-3373; further data expected this year. 5. Financial position shows a reduced net loss, improving outlook.

1. Applied DNA announces a 1-for-15 reverse stock split effective June 2, 2025. 2. Outstanding shares will be reduced from 7.8 million to approximately 519 thousand. 3. The split aims to meet Nasdaq's minimum bid price requirement of $1.00. 4. Despite the split, future compliance with Nasdaq regulations remains uncertain. 5. The company's performance uncertainty may affect investor confidence.

1. PSTV raised $15 million in financing and $2 million grant. 2. Improved cash position to $9.9 million from $0.1 million. 3. Presented positive clinical trial results for REYOBIQ™ at conference. 4. Received FDA Orphan Drug Designation for REYOBIQ™ in lung cancer. 5. CNSide® platform aims for a 2025 commercial launch.

1. DDC acquired 79 Bitcoin, increasing total holdings to 100 BTC. 2. Shares issued for Bitcoin purchase led to a 400% increase in BTC per share. 3. Partnership with Hex Trust enhances DDC's Bitcoin custody and trading security. 4. DDC positions Bitcoin as a core treasury asset amidst inflation pressures. 5. DDC's strategy aligns with growing institutional recognition of Bitcoin's value.

1. Sanofi to acquire Blueprint Medicines for approximately $9.1 billion. 2. Acquisition enhances Sanofi's portfolio in rare immunological diseases. 3. Ayvakit is the only approved treatment for systemic mastocytosis. 4. Blueprint's pipeline includes promising drugs like elenestinib and BLU-808. 5. Transaction expected to close in Q3 2025, fully accretive post-2026.